Key result
Sacubitril/valsartan has not been broadly adopted in clinical practice for patients with heart failure with reduced ejection fraction, despite being preferred in guidelines.
Why the study?
Sacubitril/valsartan is guideline-preferred over ACEIs or ARBs for patients with HFrEF, but it has not been broadly adopted in clinical practice.
This study examines the real-world adoption of sacubitril/valsartan for heart failure within a large integrated health system.
Answers are grounded in this paper and cite their sources.
Persistent low adoption of sacubitril/valsartan in HFrEF warrants review of local prescribing; leaves open barriers and implementation strategies for study.
BACKGROUND: Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for patients with heart failure with reduced ejection fraction (HFrEF). However, it has not been broadly adopted in clinical practice.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) studied this question. Sacubitril/valsartan has not been broadly adopted in clinical practice for patients with heart failure with reduced ejection fraction, despite being preferred in guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: